/PRNewswire/ OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the first patients have been enrolled in both of the Phase 2 studies.
Solid tumor patients with high Globo H or AKR1C3 expression will be enrolled. TAIPEI, Taiwan, Jan. 24, 2022 /PRNewswire/ OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced
OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.